Pharmacology and legal status of cannabidiol.

Authors

Abstract

Cannabidiol (CBD) is the second most abundant cannabinoid present in Cannabis sativa
L. It is not associated with psychotropic activity and is capable to mitigate the psychotomimetic
effects produced by tetrahydrocannabinol (THC). The latest cannabis decriminalization
policies and the high applicability in therapeutic and technologic-industrial
fields, have determined an exponential marketing growth of foods, cosmetics and in
particularly medicinal products containing CBD, which are easily available for consumers.
Most importantly, on 2018 United States Food and Drug Administration approved
CBD oral solution with the trade name of Epidiolex® for the treatment of two rare and
severe forms of epilepsy, “Lennox-Gastaut syndrome” and “Dravet syndrome”, in pediatric
patients. The aim of this review was to focus on pharmacology and on legal status
of CBD, to highlight the lack of harmonization of international regulatory laws over the
marketing authorization of CBD-based products.

Share on

Downloads

Authors

Pietro Brunetti - Università Politecnica delle Marche

Alfredo Fabrizio Lo Faro - Università Politecnica delle Marche

Filippo Pirani - Università Politecnica delle Marche

Paolo Berretta - National Centre on Addiction and Doping, ISS

Roberta Pacifici - Istituto Superiore di Sanità

Simona Pichini - National centre on Addiction and Doping, ISS

Francesco Paolo Busardò - Università Politecnica delle Marche

How to Cite
Brunetti, P., Lo Faro, A. F., Pirani, F., Berretta, P., Pacifici, R., Pichini, S., & Busardò, F. P. (2020). Pharmacology and legal status of cannabidiol. Annali dell’Istituto Superiore Di Sanità, 56(3), 285-291. Retrieved from https://annali.iss.it/index.php/anna/article/view/998
  • Abstract viewed - 267 times